Wellgistics Health stock is taking a hit today. Why is WGRX stock dropping?$105 Million Acquisition Would Expand Prescription Fulfillment AbilitiesDespite the positive news, investors are concerned that the acquisition may not be enough to turn around the negative revenue growth Wellgistics experienced in the last year. Revenue fell about half between the last two quarters, going from $7 million to $3 million. The potential $105 million acquisition, even though it’s an all-stock transaction, is clearly not ...

Core Viewpoint - Wellgistics Health Inc. has signed a $105 million Letter of Intent to evaluate a potential acquisition of Neuritek Therapeutics, which specializes in innovative therapies for neurological and psychiatric disorders [1][2]. Group 1: Acquisition Details - The proposed transaction is an all-stock deal aimed at enhancing Wellgistics' healthcare platform by expanding capabilities related to its core pharmacy distribution and services business [2]. - The acquisition is expected to strengthen the alignment between drug development and commercialization, improve pipeline visibility, and support incremental revenue opportunities [2]. - The transaction is subject to due diligence, negotiation, board approvals, and other customary closing conditions, with no assurance that a definitive agreement will be reached [3]. Group 2: Company Overview - Wellgistics Health is a technology-driven healthcare platform that integrates wholesale distribution, prescription fulfillment, and AI-driven patient access solutions [5][6]. - The company aims to capture significant market share in the fragmented healthcare sector by expanding high-margin revenue streams and deepening relationships with manufacturers [6]. Group 3: Neuritek Therapeutics Overview - Neuritek Therapeutics has developed a next-generation treatment for Post-Traumatic Stress Disorder (PTSD), which is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1) [8]. - The company was founded by Dr. William Hapworth, a psychiatrist with over 30 years of clinical research experience [8].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _____________to______________ Commission File Number: 001-42530 WELLGISTICS HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 93-32 ...

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share ELEMENT-- Press Alt+1 for screen-reader mode, Alt+0 to cancel Accessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window Back to the Newsroom Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financi ...

Core Insights - Wellgistics Health, Inc. is a leader in health information technology, focusing on integrating its AI platform EinsteinRx™ with its blockchain-enabled smart contracts platform PharmacyChain™ [1] Company Overview - The company announced a letter to shareholders from its President & Interim-CEO Prashant Patel, RPh, highlighting the rapid changes in the prescription drug and broader healthcare landscapes in the United States [1]

uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The Company makes no representation that Forzetâ"¢ is intended to diagnose, treat, cure, or prevent any disease.Wellgistics Media & ...

Core Insights - Wellgistics Health, Inc. is targeting a significant market opportunity by launching Forzet™, a medical food aimed at addressing muscle loss associated with GLP-1 agonist therapies like Ozempic and Wegovy, which are projected to grow from $70 billion in 2025 to $201 billion by 2030 [1][2] Company Overview - Wellgistics Health, Inc. integrates an AI platform, EinsteinRx™, with a blockchain-enabled smart contracts platform, PharmacyChain™, to optimize pharmacy dispensing [1] - The company connects over 6,500 pharmacies and 200 manufacturers, providing end-to-end solutions in the U.S. prescription drug market [1] Product Launch - Forzet™ is classified as a medical food for dietary management of muscle loss and is available over the counter without a prescription [1] - The product has been evaluated in clinical studies involving patients with Type 2 diabetes, heart failure, and COPD [1] Market Dynamics - The GLP-1 agonist market is experiencing rapid growth due to increasing drug potency, convenient oral formulations, and rising interest from non-obese patients seeking weight loss alternatives [1] - Key limiting factors for market expansion include side effects such as muscle loss and gastrointestinal issues [1] Strategic Positioning - Wellgistics plans to leverage Forzet™ as an adjunct solution for patients on GLP-1 agonist drugs, utilizing its EinsteinRx hub technology at the point of sale [1] - The company aims to enhance its direct-to-consumer (DTC) offerings by integrating Forzet™ into its telehealth services [1]

Core Insights - Wellgistics Health has selected five blockchain platforms to develop its PharmacyChain™ smart contracts-enabled pharmaceutical drug tracking system, which aims to support industry-wide serialization mandates [1][2] - The U.S. prescription drugs market is projected to grow from $634 billion to $883 billion by 2030, while the global blockchain in healthcare market is expected to expand from $11 billion in 2024 to $214 billion by 2030 [1][2] - Wellgistics aims to complete the development of its PharmacyChain™ by the end of Q2 2026, initially operational within its own pharmacy [1] Company Overview - Wellgistics Health, Inc. is a leader in health information technology, integrating its AI platform EinsteinRx™ with its blockchain-enabled smart contracts platform PharmacyChain™ [1] - The company connects over 6,500 pharmacies and 200 manufacturers, providing a range of services including wholesale distribution and digital prescription routing [1] - Wellgistics holds exclusive intellectual property licensed from Datavault AI, creating a competitive advantage in the $4.9 trillion U.S. healthcare market [1] Market Opportunities - The global healthcare as a service market is expected to grow from $25 billion in 2024 to $74 billion by 2030, driven by the adoption of cloud-based solutions [1] - PwC estimates a $1 trillion opportunity to shift healthcare spending towards a digital-first, proactive, and personalized care system [1] - The integration of blockchain-based smart contracts and AI is anticipated to enhance transparency and efficiency in healthcare, improving patient outcomes [1]

Datavault AI Inc. (NASDAQ:DVLT) is one of the best penny stocks under $1 to buy right now. On February 23, Datavault AI and Wellgistics Health Inc. (NASDAQ:WGRX) announced an expansion of their partnership to develop a Healthcare-as-a-Service/HaaS model powered by blockchain-enabled smart contracts. This initiative builds on their existing PharmacyChain technology, which currently digitizes the tracking of prescription drugs from script to fulfillment. The expanded collaboration will integrate Datavault ...

Core Insights - Wellgistics Health, Inc. has completed a strategic investment in a San Francisco-based mental health AI startup, enhancing its service offerings following successful beta testing [1] - The investment strengthens Wellgistics' partnership with Tollo Health, which has been expanded to support collaboration with NFL Alumni Health [1] Company Developments - Wellgistics Health integrates its proprietary pharmacy dispensing optimization AI platform, EinsteinRx™, into its blockchain-enabled smart contracts platform, PharmacyChain™ [1] - The partnership with Tollo Health subsidiary TolloCare aims to add telehealth services to Wellgistics Pharmacy, focusing on GLP-1 drug dispensing and patient engagement through mental health AI solutions [1]